Evaluation of Bone Mineral Density in Type 2 Diabetes Mellitus Patients Before and After Treatment

Overview

Journal Med J Armed Forces India

Specialty General Medicine

Date 2014 Mar 14

PMID 24623915

Citations 17

Authors

Mk Dutta

R Pakhetra

Mk Garg

Affiliations

Soon will be listed here.

Abstract

Background: The relationship between bone mineral density (BMD) and type 2 diabetes mellitus (T2DM) has been controversial. Recent studies have revealed adverse impact of antidiabetic drugs on BMD in type 2 diabetic patients. However, the influence of various antihyperglycaemic agents on BMD has not been well studied.

Method: A total of 200 patients with T2DM were screened initially for the study. Finally 67 patients (M:34, F:33) who satisfied the requirement of having been on one year of prescribed therapy were included for analysis.

Results: Bone mineral density was lower in diabetic patients as compared to controls (hip 0.962 ± 0.167 g/cm(2) vs 1.013 ± 0.184 g/cm(2), P = 0.05; spine 0.929 ± 0.214 g/cm(2) vs 1.113 ± 0.186 g/cm(2), P < 0.00001). In males BMD was significantly lower at spine (P < 0.00001) and in females BMD was significantly lower in both at the spine (P < 0.00001) and hip (P < 0.032). On multivariate analysis significant positive correlation was found between spine BMD and body mass index (BMI) (r = 0.372, P = 0.002), total cholesterol (r = 0.272, P = 0.026), low-density lipoprotein (r = 0.242, P = 0.047), and triglycerides (r = 0.282, P = 0.021). There was no correlation between BMD and glycosylated haemoglobin (r = 0.158, P = 0.265). A significant decrease in BMD at spine and hip was seen with the use of glitazones and metformin while increase was noted with sulphonylurea and its combination.

Conclusion: Men and women with T2DM have lower BMD. Bone mineral density did not have correlation to glycaemic control. Glitazones, metformin, and insulin are associated with decrease in BMD at spine, and hip, while sulphonylureas are associated with increase in BMD.

Citing Articles

Prevalence of vertebral fractures and associated factors in thai diabetic postmenopausal women.

Samakkarnthai P, Sribenjalak D, Wattanachanya L, Pongchaiyakul C Sci Rep. 2024; 14(1):22404.

PMID: 39333407 PMC: 11436870. DOI: 10.1038/s41598-024-74463-9.

Age and sex are excellent predictors of bone complications in patients with type 2 diabetes with no history of osteoporotic fracture or treatment for osteoporosis.

Yamamoto Y, Matsuba R, Nagasaka T, Shimizu S, Sakai K, Sone M J Int Med Res. 2024; 52(5):3000605241246743.

PMID: 38698517 PMC: 11304493. DOI: 10.1177/03000605241246743.

Effect of Drugs Used in Pharmacotherapy of Type 2 Diabetes on Bone Density and Risk of Bone Fractures.

Wikarek A, Grabarczyk M, Klimek K, Janoska-Gawronska A, Suchodolska M, Holecki M Medicina (Kaunas). 2024; 60(3).

PMID: 38541119 PMC: 10972440. DOI: 10.3390/medicina60030393.

Bone Mineral Density Evaluation Among Type 2 Diabetic Patients in Rural Haryana, India: An Analytical Cross-Sectional Study.

Khandelwal N, Rajauria S, Kanjalkar S, Chavanke O, Rai S Cureus. 2023; 15(9):e45908.

PMID: 37885541 PMC: 10599097. DOI: 10.7759/cureus.45908.

The Effect of Bone Quality on Treatment of Intertrochanteric Fractures with Helical Blade Versus Lag Screw Fixation in Cephalomedulary Nails.

Chong A, Schommer J, Shearer J, Timmer T, Brown A Kans J Med. 2023; 16:207-213.

PMID: 37791033 PMC: 10544885. DOI: 10.17161/kjm.vol16.20105.

References

Barrett-Connor E, Kritz-Silverstein D . Does hyperinsulinemia preserve bone?. Diabetes Care. 1996; 19(12):1388-92. DOI: 10.2337/diacare.19.12.1388. View

Ivers R, Cumming R, Mitchell P, Peduto A . Diabetes and risk of fracture: The Blue Mountains Eye Study. Diabetes Care. 2001; 24(7):1198-203. DOI: 10.2337/diacare.24.7.1198. View

Zinman B, Haffner S, Herman W, Holman R, Lachin J, Kravitz B . Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab. 2009; 95(1):134-42. DOI: 10.1210/jc.2009-0572. View

Nicodemus K, Folsom A . Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care. 2001; 24(7):1192-7. DOI: 10.2337/diacare.24.7.1192. View

Hernandez J, Olmos J, Ramos C, Martinez J, de Juan J, Valero C . Serum lipids and bone metabolism in Spanish men: the Camargo cohort study. Endocr J. 2009; 57(1):51-60. DOI: 10.1507/endocrj.k09e-228. View

Meier C, Kraenzlin M, Bodmer M, Jick S, Jick H, Meier C . Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008; 168(8):820-5. DOI: 10.1001/archinte.168.8.820. View

Lindahl E, Nyman U, Zaman F, Palmberg C, Cascante A, Shafqat J . Proinsulin C-peptide regulates ribosomal RNA expression. J Biol Chem. 2009; 285(5):3462-9. PMC: 2823421. DOI: 10.1074/jbc.M109.053587. View

Rejnmark L . Bone effects of glitazones and other anti-diabetic drugs. Curr Drug Saf. 2008; 3(3):194-8. DOI: 10.2174/157488608785699478. View

Hadzibegovic I, Miskic B, Cosic V, Prvulovic D, Bistrovic D . Increased bone mineral density in postmenopausal women with type 2 diabetes mellitus. Ann Saudi Med. 2008; 28(2):102-4. PMC: 6074519. DOI: 10.5144/0256-4947.2008.102. View

10.

Yaturu S, Humphrey S, Landry C, Jain S . Decreased bone mineral density in men with metabolic syndrome alone and with type 2 diabetes. Med Sci Monit. 2008; 15(1):CR5-9. View

11.

Zhuang Y, Miskimins W . Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal. 2008; 3:18. PMC: 2613390. DOI: 10.1186/1750-2187-3-18. View

12.

Lewiecki E, Watts N, McClung M, Petak S, Bachrach L, Shepherd J . Official positions of the international society for clinical densitometry. J Clin Endocrinol Metab. 2004; 89(8):3651-5. DOI: 10.1210/jc.2004-0124. View

13.

Yamaguchi T, Kanazawa I, Yamamoto M, Kurioka S, Yamauchi M, Yano S . Associations between components of the metabolic syndrome versus bone mineral density and vertebral fractures in patients with type 2 diabetes. Bone. 2009; 45(2):174-9. DOI: 10.1016/j.bone.2009.05.003. View

14.

Dennison E, Syddall H, Aihie Sayer A, Craighead S, Phillips D, Cooper C . Type 2 diabetes mellitus is associated with increased axial bone density in men and women from the Hertfordshire Cohort Study: evidence for an indirect effect of insulin resistance?. Diabetologia. 2004; 47(11):1963-8. DOI: 10.1007/s00125-004-1560-y. View

15.

Sosa M, Dominguez M, Navarro M, Segarra M, Hernandez D, De Pablos P . Bone mineral metabolism is normal in non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1996; 10(4):201-5. DOI: 10.1016/1056-8727(95)00062-3. View

16.

Strotmeyer E, Cauley J, Schwartz A, Nevitt M, Resnick H, Bauer D . Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med. 2005; 165(14):1612-7. DOI: 10.1001/archinte.165.14.1612. View

17.

Kahn S, Zinman B, Lachin J, Haffner S, Herman W, Holman R . Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008; 31(5):845-51. DOI: 10.2337/dc07-2270. View

18.

Dennison E, Syddall H, Aihie Sayer A, Martin H, Cooper C . Lipid profile, obesity and bone mineral density: the Hertfordshire Cohort Study. QJM. 2007; 100(5):297-303. PMC: 2080690. DOI: 10.1093/qjmed/hcm023. View

19.

van Daele P, Stolk R, Burger H, Algra D, Grobbee D, Hofman A . Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam Study. Ann Intern Med. 1995; 122(6):409-14. DOI: 10.7326/0003-4819-122-6-199503150-00002. View

20.

Suzuki K, Kurose T, Takizawa M, Maruyama M, Ushikawa K, Kikuyama M . Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density. Diabetes Res Clin Pract. 2005; 68(2):117-25. DOI: 10.1016/j.diabres.2004.08.006. View